AR023659A1 - Un compuesto inhibidor de p38, una composicion farmaceutica que lo comprende y el uso de dicha composicion en el tratamiento y prevencion de estados patologicos - Google Patents
Un compuesto inhibidor de p38, una composicion farmaceutica que lo comprende y el uso de dicha composicion en el tratamiento y prevencion de estados patologicosInfo
- Publication number
- AR023659A1 AR023659A1 ARP990104643A ARP990104643A AR023659A1 AR 023659 A1 AR023659 A1 AR 023659A1 AR P990104643 A ARP990104643 A AR P990104643A AR P990104643 A ARP990104643 A AR P990104643A AR 023659 A1 AR023659 A1 AR 023659A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- inhibitor compound
- hydrogen
- prevention
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Un compuesto inhibidor de la p38, la que es una proteinquinasa implicada en proliferacion celular, muerte celular y respuesta a estímulos extracelulares.Más particularmente, la presente invencion se refiere a un compuesto inhibidor de p38,caracteriz ado por la formula (1) o tautomeros del mismo o salesfarmacéuticamente aceptables del mismo; en donde: HET es un heterociclo de 5-7 miembros con 1 a 4 átomos de N, S u O, heterociclo que está sustituido con 1 a 3grupos alquilo C1-4, decadena recta o ramificada, y está sustituido opcionalmente con halo, ciano, N(R)2, OR, CO2R, CON(R)2, y SO2N(R2)2; X es O o NR;n es 1 a 3; R es seleccionado de hidrogeno, alquilo C1-3, alquenilo C2-3 o alquinilo C2-3 fenilo o fenilo sustituido con 1a 3 sustituyen tes seleccionadosindependientemente de halo, metoxi, ciano, nitro, amino, hidroxi, metilo o etilo; R1 es seleccionado de hidrogeno, alquilo C1-3, OH, u O-(alquilo C1-3); R2 esseleccionado de hidrogeno, alquilo C1-3, o alquenilo C1-3;estando cada uno sustituido opcionalmente con -N(R)2, -OR, SR, -C(O)-N(R)2, --S(O2)-N(R)2, C(O)-OR,o R3 es seleccionado de sistemas de un anillo carbocíclico aromático de 5-6 miembros o heterocíclico. La invencion se refiere también a métodosparaproducir estos inhi bidores, a composiciones farmacéuticas que los comprenden y al uso de dichas composiciones en el tratamiento y la prevencion de variosestados patologicos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10101398P | 1998-09-18 | 1998-09-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR023659A1 true AR023659A1 (es) | 2002-09-04 |
Family
ID=22282668
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP990104643A AR023659A1 (es) | 1998-09-18 | 1999-09-15 | Un compuesto inhibidor de p38, una composicion farmaceutica que lo comprende y el uso de dicha composicion en el tratamiento y prevencion de estados patologicos |
Country Status (13)
Country | Link |
---|---|
US (2) | US6635644B2 (es) |
EP (1) | EP1114051B1 (es) |
JP (1) | JP2002526501A (es) |
AR (1) | AR023659A1 (es) |
AT (1) | ATE236167T1 (es) |
AU (1) | AU761599B2 (es) |
CA (1) | CA2339253C (es) |
DE (1) | DE69906554T2 (es) |
DK (1) | DK1114051T3 (es) |
ES (1) | ES2192864T3 (es) |
MY (1) | MY117696A (es) |
PT (1) | PT1114051E (es) |
WO (1) | WO2000017204A1 (es) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4993838B2 (ja) * | 2000-08-11 | 2012-08-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | P38のインヒビターとしてのピリジン誘導体 |
ATE415162T1 (de) | 2001-06-11 | 2008-12-15 | Vertex Pharma | Isochinolin-inhibitoren von p38 |
WO2003059891A1 (en) * | 2002-01-18 | 2003-07-24 | Pharmacia Corporation | Substituted pyridazinones as inhibitors of p38 |
EP1534282B1 (en) | 2002-07-09 | 2006-12-27 | Boehringer Ingelheim Pharma GmbH & Co.KG | Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases |
WO2004019873A2 (en) | 2002-08-29 | 2004-03-11 | Scios Inc. | Methods of promoting osteogenesis |
KR20050111314A (ko) | 2002-12-20 | 2005-11-24 | 암젠 인코포레이션 | 천식 및 알레르기성 염증 조절제들 |
KR20060025141A (ko) | 2003-05-15 | 2006-03-20 | 아르퀼 인코포레이티드 | P38의 억제제 및 이를 사용하는 방법 |
WO2005007632A1 (en) * | 2003-07-18 | 2005-01-27 | Pharmacia Corporation | Substituted pyridazinones as inhibitors of p38 |
WO2005030091A2 (en) | 2003-09-25 | 2005-04-07 | Scios Inc. | Stents and intra-luminal prostheses containing map kinase inhibitors |
JP4608888B2 (ja) * | 2004-01-23 | 2011-01-12 | 宇部興産株式会社 | 2−シアノ−2−(4−テトラヒドロピラニル)酢酸エステルの製法 |
WO2006010082A1 (en) | 2004-07-08 | 2006-01-26 | Arqule, Inc. | 1,4-disubstituted naphtalenes as inhibitors of p38 map kinase |
US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
US20070054916A1 (en) * | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
EP2258704A1 (en) | 2004-10-19 | 2010-12-08 | ArQule, Inc. | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase |
PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
EP1676574A3 (en) | 2004-12-30 | 2006-07-26 | Johnson & Johnson Vision Care, Inc. | Methods for promoting survival of transplanted tissues and cells |
US20060178388A1 (en) * | 2005-02-04 | 2006-08-10 | Wrobleski Stephen T | Phenyl-substituted pyrimidine compounds useful as kinase inhibitors |
US7759337B2 (en) * | 2005-03-03 | 2010-07-20 | Amgen Inc. | Phthalazine compounds and methods of use |
ES2349131T3 (es) | 2005-07-21 | 2010-12-28 | F. Hoffmann-La Roche Ag | Derivados de piridazinona como agonistas del receptor de la hormona tiroidea. |
US7482345B2 (en) * | 2005-12-05 | 2009-01-27 | Meng-Hsin Chen | P38 kinase inhibiting agents |
SI1976828T1 (sl) | 2005-12-29 | 2017-07-31 | Celtaxsys, Inc. | Diaminski derivati kot inhibitorji levkotrien A4 hidrolaze |
CA2649543A1 (en) * | 2006-04-21 | 2007-11-01 | Amgen Inc. | Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use |
ES2400695T3 (es) * | 2006-07-17 | 2013-04-11 | Amgen Inc. | Derivados de quinazolina y piridopirimidina como inhibidores de la cinasa p38 |
WO2008030466A1 (en) * | 2006-09-05 | 2008-03-13 | Amgen Inc. | Phthalazine, aza- and diaza-phthalazine compounds and methods of use |
ATE542818T1 (de) * | 2006-10-11 | 2012-02-15 | Amgen Inc | Imidazo- und triazolopyridinverbindungen und verfahren zu deren anwendung |
WO2008114119A2 (en) * | 2007-03-20 | 2008-09-25 | Cadila Pharmaceuticals Limited | P38 inhibitors |
CA2685597C (en) | 2007-05-07 | 2012-10-02 | Amgen Inc. | Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as p38 modulators, process for their preparation, and their pharmaceutical use |
WO2008137176A1 (en) * | 2007-05-07 | 2008-11-13 | Amgen Inc. | Pyrazolo-pyridinone compounds, process for their preparation, and their pharmaceutical use |
EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
US8314131B2 (en) * | 2007-09-21 | 2012-11-20 | Amgen Inc. | Triazole fused heteroaryl compounds and methods of use thereof |
WO2009078992A1 (en) * | 2007-12-17 | 2009-06-25 | Amgen Inc. | Linear tricyclic compounds as p38 kinase inhibitors |
ES2471919T3 (es) | 2007-12-19 | 2014-06-27 | Amgen, Inc | Derivados de ácido fenilac�tico como moduladores de inflamación |
US8367671B2 (en) * | 2008-03-21 | 2013-02-05 | Amgen Inc. | Pyrazolo[3.4-B]pyrazine compounds as p38 modulators and methods of use as anti-inflamatory agents |
US8420649B2 (en) | 2008-08-29 | 2013-04-16 | Amgen Inc. | Pyrido[3,2-d]pyridazine-2(1H)-one compounds as p38 modulators and methods of use thereof |
US8455495B2 (en) | 2008-08-29 | 2013-06-04 | Amgen Inc. | Pyridazino-pyridinone compounds and methods of use |
US8497269B2 (en) | 2008-10-10 | 2013-07-30 | Amgen Inc. | Phthalazine compounds as p38 map kinase modulators and methods of use thereof |
WO2010042646A1 (en) | 2008-10-10 | 2010-04-15 | Amgen Inc. | Aza- and diaza-phthalazine compounds as p38 map kinase modulators and methods of use thereof |
US8906677B2 (en) | 2008-12-17 | 2014-12-09 | The Scripps Research Institute | Generation and maintenance of stem cells |
GB0902648D0 (en) * | 2009-02-17 | 2009-04-01 | Argenta Discovery Ltd | Pharmaceutical compounds and compositions |
GB0908317D0 (en) * | 2009-05-14 | 2009-06-24 | Argenta Discovery Ltd | Pharmaceutical compounds and compositions |
US8809372B2 (en) | 2011-09-30 | 2014-08-19 | Asana Biosciences, Llc | Pyridine derivatives |
US9199975B2 (en) | 2011-09-30 | 2015-12-01 | Asana Biosciences, Llc | Biaryl imidazole derivatives for regulating CYP17 |
WO2013162027A1 (ja) | 2012-04-27 | 2013-10-31 | 学校法人 慶應義塾 | 神経分化促進剤 |
EP2968359B1 (en) | 2013-03-12 | 2021-01-20 | Celltaxis, LLC | Methods of inhibiting leukotriene a4 hydrolase |
EP2970309A4 (en) | 2013-03-14 | 2016-11-09 | Celtaxsys Inc | INHIBITORS OF LEUCOTRIENE A4 HYDROLASE |
EP2968265A4 (en) | 2013-03-14 | 2016-12-28 | Celtaxsys Inc | INHIBITORS OF THE LEUKOTRIEN A4 HYDROLASE |
EP2968264A4 (en) | 2013-03-14 | 2016-11-02 | Celtaxsys Inc | INHIBITORS OF LEUCOTRIENE A4 HYDROLASE |
EP3368052B1 (en) | 2015-10-27 | 2021-12-08 | Children's Hospital Medical Center | Use of mapk inhibitors to reduce loss of hematopoietic stem cells during ex vivo culture and genetic manipulation |
US20190060286A1 (en) | 2016-02-29 | 2019-02-28 | University Of Florida Research Foundation, Incorpo | Chemotherapeutic Methods |
US10889548B2 (en) | 2018-03-26 | 2021-01-12 | Clear Creek Bio, Inc. | Compositions and methods for inhibiting dihydroorotate dehydrogenase |
AU2019278935A1 (en) | 2018-05-31 | 2020-12-10 | Celltaxis, Llc | Method of reducing pulmonary exacerbations in respiratory disease patients |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6147080A (en) * | 1996-12-18 | 2000-11-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
JP4993838B2 (ja) * | 2000-08-11 | 2012-08-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | P38のインヒビターとしてのピリジン誘導体 |
-
1999
- 1999-09-15 AR ARP990104643A patent/AR023659A1/es unknown
- 1999-09-16 DE DE69906554T patent/DE69906554T2/de not_active Expired - Lifetime
- 1999-09-16 WO PCT/US1999/021567 patent/WO2000017204A1/en active IP Right Grant
- 1999-09-16 PT PT99948314T patent/PT1114051E/pt unknown
- 1999-09-16 EP EP99948314A patent/EP1114051B1/en not_active Expired - Lifetime
- 1999-09-16 DK DK99948314T patent/DK1114051T3/da active
- 1999-09-16 AU AU61521/99A patent/AU761599B2/en not_active Ceased
- 1999-09-16 CA CA002339253A patent/CA2339253C/en not_active Expired - Fee Related
- 1999-09-16 ES ES99948314T patent/ES2192864T3/es not_active Expired - Lifetime
- 1999-09-16 AT AT99948314T patent/ATE236167T1/de not_active IP Right Cessation
- 1999-09-16 JP JP2000574113A patent/JP2002526501A/ja active Pending
- 1999-09-17 MY MYPI99004032A patent/MY117696A/en unknown
-
2001
- 2001-03-16 US US09/809,921 patent/US6635644B2/en not_active Expired - Fee Related
-
2003
- 2003-09-08 US US10/658,111 patent/US7169779B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ATE236167T1 (de) | 2003-04-15 |
DE69906554D1 (de) | 2003-05-08 |
CA2339253C (en) | 2009-04-07 |
US20040142927A1 (en) | 2004-07-22 |
CA2339253A1 (en) | 2000-03-30 |
ES2192864T3 (es) | 2003-10-16 |
US20020010170A1 (en) | 2002-01-24 |
EP1114051B1 (en) | 2003-04-02 |
US6635644B2 (en) | 2003-10-21 |
PT1114051E (pt) | 2003-07-31 |
DE69906554T2 (de) | 2004-07-01 |
WO2000017204A1 (en) | 2000-03-30 |
US7169779B2 (en) | 2007-01-30 |
MY117696A (en) | 2004-07-31 |
DK1114051T3 (da) | 2003-07-14 |
AU6152199A (en) | 2000-04-10 |
EP1114051A1 (en) | 2001-07-11 |
AU761599B2 (en) | 2003-06-05 |
JP2002526501A (ja) | 2002-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR023659A1 (es) | Un compuesto inhibidor de p38, una composicion farmaceutica que lo comprende y el uso de dicha composicion en el tratamiento y prevencion de estados patologicos | |
UY25811A1 (es) | Derivados de pirrolidina que son antagonistas del receptor ccr-3 | |
AR041566A1 (es) | Derivados de indol utiles para el tratamiento de enfermedades | |
CO4600636A1 (es) | Derivados de indazol | |
AR024969A1 (es) | Derivados de 8-fenil-6,9-dihidro-[1,2,4]triazol[3,4-i]purin-5-ona | |
AR044506A1 (es) | Inhibidores ciclicos de la proteina tirosina cinasa | |
DOP2002000349A (es) | Nuevos compuestos antiinflamatorios de bencimidazol | |
AR029383A1 (es) | Moleculas pequenas, los intermediarios para su sintesis, las composiciones farmaceuticas que las contienen y su uso para preparar un medicamento destinado al tratamiento o la profilaxis de enfermedades inflamatorias o mediadas por celulas inmunes | |
AR018311A1 (es) | Compuestos de imidazopirazinas sustituidas con heterociclos, utiles como inhibidores de la proteina tirosina cinasa, las composiciones farmaceuticas quelos contienen y el procedimiento para preparar compuestos intermediarios en la sintesis de las mismas. | |
PE20050652A1 (es) | Mezclas que contienen estrobilurinas y moduladores de etileno | |
AR034448A1 (es) | Uso de derivados de nucleosidos, dichos derivados de nucleosidos para dicho uso, composiciones farmaceuticas que los comprenden y uso de dichas composiciones | |
YU18999A (sh) | Supstituisani tricikli | |
DK285285D0 (da) | N-(2-nitrophenyl)-2-amino-pyrimidin-derivater samt deres fremstilling og anvendelse i midler til bekaempelse af skadelige mikroorganismer | |
HUP0400757A2 (hu) | Protein kináz gátló hatású kondenzált pirazolszármazékok és ezeket tartalmazó gyógyszerkészítmények | |
HRP20010193B1 (en) | Synergistic active substance combinations for controlling harmful plants | |
ATE425142T1 (de) | Inhibitoren von c-jun n-terminal kinasen (jnk) | |
AR012489A1 (es) | Tiofenopiridinas antagonistas del factor de liberacion de corticotropina. procedimiento para su preparacion, el uso de las mismas en la preparacionde un medicamento, composicion farmaceutica que las comprende, procedimiento para la preparacion de dicha composicion, un compuesto intermediario y | |
HUP0300444A2 (hu) | Kálciumblokkolót tartalmazó stabilizált gyógyszerkészítmények | |
CO5040004A1 (es) | 2-4-diamino-1,3,5-triazinas, su preparacion y empleo como herbicidas y fitorreguladores | |
TR200000725T2 (tr) | Bir monoamin oksidaz inhibitörü ve h5-HT1B antagonistinin bileşimi | |
BR0211171A (pt) | Compostos quìmicos | |
AR007108A1 (es) | Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes. | |
ES2116467T3 (es) | Derivados de 5h,10h-imidazo(1,2-a)indeno(1,2-e)pirazina-4-ona, su preparacion y los medicamentos que les contienen. | |
AP9901578A0 (en) | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents. | |
HUP0303020A2 (hu) | Androgén 7-szubsztituált 11-halogénezett szteroidok, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |